{"url_path":"/sec/neup/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1191070/0001193125-26-225442-index.html","accession_number":"0001193125-26-225442","cik":"0001191070","ticker":"NEUP","issuer_name":"Neuphoria Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1191070/0001193125-26-225442-index.html","primary_entity_key":"0001191070","primary_entity_name":"Neuphoria Therapeutics Inc."},"word_count":244,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\nExhibit\n\nNumber\n\n \n\nDescription\n\n31.1*\n\n \n\n[Certification of the principal executive officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](neup-ex31_1.htm)\n\n31.2*\n\n \n\n[Certification of the principal financial officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](neup-ex31_2.htm)\n\n32.1**\n\n \n\n[Certification of the principal executive officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](neup-ex32_1.htm)\n\n32.2**\n\n \n\n[Certification of the principal financial officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](neup-ex32_2.htm)\n\n101.INS\n\n \n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents\n\n24\n\n \n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n* Filed herewith.\n\n** Furnished herewith\n\n+ Indicates a management or compensatory plan\n\n25\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\nCompany\n\n \n\n \n\n \n\n \n\nDate: May 15, 2026\n\n \n\nBy:\n\n/s/ Spyridon Papapetropoulos\n\n \n\n \n\n \n\nSpyridon Papapetropoulos\n\n \n\n \n\n \n\nInterim Chief Executive Officer and Director\n\n \n\n \n\n \n\nDate: May 15, 2026\n\n \n\nBy:\n\n/s/ Tim Cunningham\n\n \n\n \n\n \n\nTim Cunningham\n\n \n\n \n\n \n\nChief Financial Officer\n\n \n\n26"}